Secondary Logo

Journal Logo

Institutional members access full text with Ovid®

Ifosfamide plus Mitoxantrone as Salvage Treatment in Non-Hodgkin's Lymphomas

Lorusso, V., M.D.; Paradise, A., M.D.; Guida, M., M.D.; Berardi, F., M.D.; Lena, M. De, M.D.

American Journal of Clinical Oncology: December 1991 - Volume 14 - Issue 6 - p 492–495
Original Article: PDF Only

wenty-two patients affected by relapsed or refractory nonHodgkin's lymphoma (NHL) were treated with a combination of ifosfamide (IFO) at the dose of 1.2 g/m2 intravenous (i.v.) (1 h infusion) for 5 consecutive days with mesna as uroprotector plus mitoxantrone (NOV) at the dose of 12 mg/ m2 i.v. on day 1; both drugs were recycled every 3–4 weeks. Of 21 evaluable patients, overall response observed was 57% (38% complete response and 19% partial response with a median duration of response of 7 months (5–23+). Dose-limiting toxicity was represented by leukopenia (grade III-IV in 43% of cases); severe thrombocytopenia was observed less frequently (grade III-IV in 19% of cases). This hematologic toxicity prevented administration of therapy every 3 weeks as initially planned. However, the complete hematological recovery, usually observed at the fourth week, permitted therapy administration to all patients without dose reduction. Lowgrade lymphomas responded to treatment as well as intermediate or high grade lymphomas. Moreover, patients treated with third- or fourth-line chemotherapy also responded. However, response was observed in 11/13 (85%) relapsed patients as compared to 2/8 (25%) refractory cases. The combination of IFO plus NOV is active in heavily pretreated patients with NHL. Nevertheless, the study of a larger number of patients is necessary to better define the exact role of this combination as “salvage” therapy for NHL.

Medical Oncology Division, Oncologic Institute, Bari, Italy.

© Lippincott-Raven Publishers.